Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) was founded in 2014 and is headquartered in Houston, Texas, USA, with 7 full-time employees. It is a clinical-stage biotechnology company dedicated to the development of cancer treatments based on epigenetics method.
Salarius Pharmaceuticals, Inc. (SLRX):
Salarius Pharmaceuticals is an emerging biotechnology company dedicated to the development of targeted therapies to treat pediatric and other cancers, including advanced solid tumors. Salarius Pharmaceuticals’ leading compound, Seclidemstat, represents a potential paradigm shift in cancer treatment. The company initially targeted Ewing’s sarcoma, a destructive pediatric, adolescent, and young adult bone cancer that currently has no targeted therapy.
Salarius Pharmaceuticals’ main drug candidate is Seclidemstat (SP-2577), which is in phase I/II clinical trials for the treatment of advanced solid tumors, including prostate cancer, breast cancer and ovarian cancer, and Ewing’s sarcoma.
Salarius believes that, compared with other treatments targeting LSD1 in clinical development, Seclidemstat may have the potential to improve safety and efficacy. Salarius is also developing Seclidemstat for many cancers with unmet needs, and expects to target other clinical studies on advanced solid tumors in 2019, including prostate cancer, breast cancer and ovarian cancer.
Salarius Pharmaceuticals, Inc. has established a strategic partnership with The University of Utah Research Foundation to protect the patent rights of SP-2577 and its related compounds with an exclusive license; developed in South Korea in cooperation with HLB Life Sciences, Produce, manufacture, use and sell the drug; and conduct product development activities with the Cancer Prevention and Research Institute of Texas.